TMJ - A WELL-TOLERATED HIGH-DOSE REGIMEN FOR THE ADJUVANT CHEMOTHERAPY OF HIGH-RISK BREAST-CANCER

Following local treatment and doxorubicin-containing standard chemothe rapy, 42 patients with surgical Stage II or IIIA breast cancer contain ing ten or more involved axillary nodes and 13 patinets with Stage III B disease were treated with high-dose chemotherapy (TMJ) consisting of thiotepa (750 mg/m2), mitoxantrone (40 mg/m2), and carboplatin (1000 mg/m2), with autologous bone marrow (ABM) and peripheral stem cell (PS C) transplant, followed by irradiation and/or hormone therapy. Sargram ostim (GM-CSF) support was given to most patients. The median time to transfusion independence was two weeks. Severe nonhematologic toxicity was uncommon, with no intensive care admission or treatment-related d eath. At a median follow-up of 17 months, eight patients have relapsed and five have died of tumor progression. No statement can yet be made regarding adjuvant efficacy, but this high-dose regimen is very well tolerated.